Cytonic products are revolutionary formulas specifically engineered to fortify your body’s trillions of cells, more specifically the cells of your immune system. Cytonic - Cyto (cell) + Tonic (elixir). Cytonics are powerful, natural health products containing Vitamin D Transport Protein (VDTP), a glycoprotein sometimes referred to as GcMAF.
We consume proteins everyday - they help to keep us strong & healthy. Cytonic products contain the specific protein required to feed our immune cells, VDTP. In our ISO and GMP registered laboratory, we extract VTDP from bovine colostrum and then filter it many, many times until only the proteins remain—there is absolutely no casin present.
Let’s take a look at what cytonic products comprise of and how theyregulate immune system function.
Cytoproteins (cyto meaning cell) are proteins that activate cells. There are 482 cytoproteins on the vitamin D transport protein chain and each activates a specific type of cell in our body. Feeding our immune cells is one very important function of Cytoproteins, another major function is the transport of vitamins & fatty acids o build and repair cells as well as removing toxins from the body. This vital function earns the name 'transport protein'
Read more: What are Cytonic VDTP / GcMAF products?
Autism spectrum disorders (ASD) are developmental disorders affecting 1:88 children, and which appear to be associated with a variety of complex immune dysregulations including autoimmunity. The enzyme, alpha-N-acetylgalactosaminidase (Nagalase) deglycosylates Vitamin D Binding Protein (VDBP) rendering it incapable of activating macrophage defenses. Increased Nagalase activity has been associated with a variety of malignancies, immune disorders and viral infections. Macrophage activating factor (MAF) has been repeatedly published as an intervention to lower serum Nagalase activity for a variety of cancer and HIV patients.
MAF is a naturally occurring protein with well-established safety and therapeutic benefit(s) supported by numerous human studies.
Read more: Immune dysfunction in autism
We need to change our paradigm from the existing one that symptoms are directly due to the pathogen or insult to the understanding that the symptoms and in fact clinical markers are due to the immune response. So instead of believing shingles erupts or herpes erupts or cystitis symptoms erupt when our immunity is depressed, we see these eruptions as an immune activation. Of course, if there are factors suppressing immune function then these reactions will be ineffective long term. But our routine approach of suppressing symptoms when faced with an “acute illness” is likely promoting chronic problems.
The immune response in autism
Read more: Manifestations of the disease
Protein concentration of unprocessed VDTP preparation has been determined by Bradford assay (IB-16.05.00). After processing, VDTP final solutions were prepared in concentrations: 167 ng/ml; 1,000 ng/mI and 3,334 ng/mI (±10%) in relation to initial concentration.
1. Formulation and characteristics
Formulation and characteristic parameters have been confirmed organoleptically.
2. Protein concentration
Protein concentration of unprocessed VDTP preparation has been determined by Bradford assay (IB-16.05.00).
After processing, VDTP final solutions were prepared in concentrations:
167 ng/ml; 1,000 ng/mI and 3,334 ng/mI (±10%) in relation to initial concentration.
Read more: GcMAF Cytonic Supplement - Analytical Parameters
Immuntherapy for Prostate Cancer with Gc Protein-Derived Macrophage Activating Factor
16 nonanemic prostate cancer patients received weekly administration of 100 ng of GcMAF. After 14 to 25 weekly administrations of GcMAF (100 ng/week), all 16 patients had levels equivalent to those of healthy control values, indicating that these patients are tumor-free. No recurrence occurred for 7 years.
Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto: GcMAF, Translational Oncologie: Vol 1, No 2: 65-72 (2008a)
Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)
Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). After about 16-22 administrations (approximately 3.5-5 months) of GcMAF, these patients had insignificantly low serum enzyme levels indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years.
Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto, Naofumi Ushijima: International Journal of Cancer 122: 461-467 (2008b)
Read more: Some more GcMAF research papers
Often the question arises about the molecule known as GcMAF - we hope you find the following information useful:
In 2008-2009, four human studies appeared claiming fantastic results for a groundbreaking new cancer treatment. The studies were conducted Dr. Nabuto Yamamoto, who at the time was a Professor of Biochemistry at Temple University Medical School in Philadelphia. He was assisted by a team of other researchers.
If the results hold up then the new treatment, a natural protein found in a healthy human body, could be one of the most exciting new cancer developments ever seen.
In the first study, Dr. Yamamoto supplied the protein to doctors treating HIV patients resulting in complete eradication of the infection. After seven years follow-up, their blood counts remained normal.
In another study, the Yamamoto team treated 16 non-anemic metastatic breast cancer patients with a single injection of 100 nanograms of GcMAF per week for 22 weeks.
In the third study, all 16 non-anemic metastatic prostate patients were tumour free after 24 weeks and remained so at seven years follow-up.
In the fourth study, all eight non-anemic metastatic colorectal patients were cancer-free after 48 weeks and remained so at seven years follow-up as confirmed by CT scans.
In short, and astonishing as it sounds, Professor Yamamoto achieved a 100% remission rate in metastatic cancer patients.
The discovery didn't happen overnight. It was the product of years of research at a respected mainstream medical institution.
Read more: What is GcMAF?
"Immune system dysregulation is well-recognized in autism and thought to be part of the etiology of this disorder.
The endocannabinoid system is a key regulator of the immune system via the cannabinoid receptor type 2 (CB2R) which is highly expressed on macrophages and microglial cells.
The use of the Gc protein-derived Macrophage Activating Factor (GcMAF), an endogenous glycosylated vitamin D binding protein responsible for macrophage cell activation has demonstrated positive effects in the treatment of autistic children.
In this current study, we investigated the in vitro effects of GcMAF treatment on the endocannabinoid system gene expression, as well as cellular activation in blood monocyte-derived macrophages (BMDMs) from autistic patients compared to age-matched healthy developing controls.
Read more: The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and...
In brief, autism is a group of disorders with genetic and environmental causes. ASD children have evidence of abnormalities in the brain during the first 2 years of life. This may be attributed to inflammation, and the lymph flow from the meningeal lymphatic system in the brain may be a factor.
ASD children appear to have increased cerebrospinal fluid (CSF) in the folds and spaces around the brain (extra-axial spaces). Increased extra-axial spaces correlate with an increase in severity of autism symptoms, and the reason for the increase in the fluid has only recently been discovered.
Read more: Brain inflammation & associated autism disorders
Abstract & Background
Autism spectrum disorders (ASD) are developmental disorders affecting 1:88 children, and which appear to be associated with a variety of complex immune dysregulations including autoimmunity. The enzyme, alpha-N-acetylgalactosaminidase (Nagalase) deglycosylates serum Gc protein (vitamin D3 – binding protein) rendering it incapable of activating macrophage defenses. Increased Nagalase activity has been associated with a variety of malignancies, immune disorders, viral and bacterial infections.
Macrophage activating factor (GcMAF) has been repeatedly published as an intervention to lower serum Nagalase activity for a variety of cancer and HIV patients. GcMAF is a naturally occurring protein with well-established safety and therapeutic benefits supported by numerous human studies.
Read more: Dr Bradstreet's paper on Autism, Nagalase & GcMAF
Autistic disorder (autism) is a behaviorally defined developmental disorder with a wide range of behaviors. Although the etiology of autism is unknown, data suggest that autism results from multiple etiologies with both genetic and environmental contributions, which may explain the spectrum of behaviors seen in this disorder.
One proposed etiology for autism is viral infection very early in development. The mechanism, by which viral infection may lead to autism, be it through direct infection of the central nervous system (CNS), through infection elsewhere in the body acting as a trigger for disease in the CNS, through alteration of the immune response of the mother or offspring, or through a combination of these, is not yet known.
Animal models in which early viral infection results in behavioral changes later in life include the influenza virus model in pregnant mice and the Borna disease virus model in newborn Lewis rats.
Many studies over the years have presented evidence both for and against the association of autism with various viral infections. The best association to date has been made between congenital rubella and autism; however, members of the herpes virus family may also have a role in autism.
Recently, controversy has arisen as to the involvement of measles virus and/or the measles, mumps, rubella (MMR) vaccine in the development of autism.
Biological assays lend support to the association between measles virus or MMR and autism whereas epidemiologic studies show no association between MMR and autism.
Further research is needed to clarify both the mechanisms whereby viral infection early in development may lead to autism and the possible involvement of the MMR vaccine in the development of autism.
J Neurovirol. 2005 Feb;11(1):1-10.
Libbey JE, Sweeten TL, McMahon WM, Fujinami RS.
Department of Neurology, University of Utah, Salt Lake City, Utah 84132-2305, USA.